Journal of Clinical Oncology
Articles in this Issue
Comparing RECIST, Choi, modified Choi (mChoi) and viable tumor volume (VTV) in predicting clinical benefit of vascular endothelial growth factor receptor inhibitors (VEGFRi) in patients (pts) with recurrent/metastatic (R/M) adenoid cystic carcinoma (ACC).
e18145 Background: RECIST may underestimate the clinical activity of systemic therapies for ACC, especially in pts with ACC-II molecular subtype receiving...
Therapeutic impact of novel agents in patients with stage IV de novo HR+ve/Her2-ve breast cancer: Results from a real world dataset.
1085 Background: The objective of this retrospective analysis was to look at the therapeutic impact of CDK4/6i and novel agents among pts with stage IV De...
Survival analysis of metastatic Merkel cell carcinoma patients pre- and post-immunotherapy era in the US: A retrospective population-based study.
e21515 Background: In 2017, the U.S. Food and Drug Administration (FDA) approved the first immunotherapy (avelumab) to treat metastatic Merkel cell carcin...
Larotrectinib resistance in TRK fusion cancers: Analysis of a tumor-agnostic, global clinical trial dataset.
3066 Background: Larotrectinib (laro) is the first-in-class, highly selective, TRK inhibitor approved for tumor- and age-agnostic use in TRK fusion cancer...
Efficacy and safety of fedratinib in myelofibrosis patients after ruxolitinib: A systematic review and meta-analysis.
e18592 Background: Myelofibrosis is a rare myeloproliferative neoplasm characterized by bone marrow fibrosis, splenomegaly...
Hepatoprotective effects and safety profile of donafenib combined with transarterial chemoembolization in unresectable hepatocellular carcinoma.
e16176 Background: The efficacy of donafenib in combination with transarterial chemoembolization (TACE) has been established for unresectable hepatocellul...
Early-onset (EO) cancer trends in Brazil: A comprehensive analysis of hospital-based cancer registry data (2000–2019).
10552 Background: The rising incidence of early-onset (EO) cancers (< 45 years) since the 1990s presents a global public health challenge. In Brazil, H...
Prognostic role of estrogen receptor (ER) expression in breast cancer (BC) metastases and its dynamics from primary to metastatic disease: Results from a large multicentric cohort of patients with phenotypically stable ER+(≥10%)/HER2- BC.
1067 Background: ER expression is one of the main determinants of prognosis in patients (pts) with BC. Phenotypic conversion from ER+ (ER>=10%)/HER2- p...
Gender and racial disparities in survival from head and neck cancer: A competing events analysis of Kaiser Permanente patients.
e18048 Background: Outcomes for patients with head and neck cancer (HNC) are affected by tumor specific features, as well as demographic characteristics a...
The development of the cost of cancer in 31 European countries.
1596 Background: The estimated number of new cancer cases in Europe has risen from 2.6 million in 1995 to 4.1 million in 2022. Around every fourth death i...
Pediatric patients with tenosynovial giant cell tumor: Real-world results from an observational registry.
11544 Background: Tenosynovial giant cell tumor (TGCT) is a rare, locally aggressive tumor originating in the synovial lining of the joint, bursa, and ten...
Pathologic complete response to neoadjuvant chemotherapy in early-stage male breast cancer across molecular subtypes and racial/ethnic groups.
550 Background: Male breast cancer (mBC) accounts for ~1.0% of all breast cancers in the U.S. Neoadjuvant chemotherapy (NACT) is often used to downsize lo...
Survival disparities in patients with acute lymphoblastic leukemia: A focus on young adult and adolescent patients.
e18529 Background: Acute lymphoblastic leukemia (ALL) in the pediatric population has a 5-year overall survival that exceeds 90%, however, the survival ra...
Comparison of capecitabine plus oxaliplatin (CAPOX) vs paclitaxel plus carboplatin (PC) as chemotherapy in definitive chemo-radiotherapy (CRT) in carcinoma esophagus: A prospective study from a tertiary cancer center in north India.
e16100 Background: Definitive chemo-radiotherapy (dCRT) is standard of treatment for unresectable, non-metastatic esophageal cancers. Both CapOx and PC ar...
Use of GIP and GLP-1 receptor agonists in prostate cancer patients.
5024 Background: The use of glucagon-like peptide 1 receptor agonist (GLP-1 RA) and dual glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 RA (...
Multidisciplinary integrative medicine as tailored treatment for cancer patients: A multicentre, retrospective, case series study.
e13896 Background: Integrative Medicine (IM) combines traditional medicine (TM) with complementary and alternative medicine (CAM). Despite the controversi...
Enhancing prognostic precision in bladder cancer: AI-driven tumor microenvironment analysis from H&E images.
3017 Background: Bladder cancer (BC) represents a significant healthcare burden. Despite advancements in diagnostics and treatment, the survival rate rema...
Survival disparities between patients with breast cancer with and without HIV at Jaramogi Oginga Odinga Teaching and Referral Hospital (JOOTRH).
1622 Background: Breast cancer and HIV/AIDS pose significant public health challenges. Women living with HIV face higher mortality rates when diagnosed wi...
Circulating tumor DNA (ctDNA) monitoring in patients (pts) with advanced urothelial carcinoma (aUC) treated with enfortumab vedotin +/- pembrolizumab (EVP).
4560 Background: CtDNA is an emerging biomarker in aUC, but its role for pts receiving EVP is unclear. Methods: We undertook a ret...
NVL-330, a selective HER2 tyrosine kinase inhibitor, in patients with advanced or metastatic HER2-altered non-small cell lung cancer: The phase 1 HEROEX-1 study.
TPS8665 Background: Oncogenic mutations and gene amplifications in the HER2 receptor tyrosine kinase are detected in approximately 2-4% and 1-5% of non-sm...
Association between cost and insurance on receipt of guideline-concordant mammography.
11078 Background: Many organizations offer mammography guidelines with slight differences, which can serve as a barrier to receiving a mammogram. Furtherm...
Regorafenib response prediction in metastatic colorectal cancer by a novel genomic and transcriptomic model.
3135 Background: The multi-kinase inhibitor regorafenib (Rego) is approved for the treatment of refractory metastatic colorectal cancer (CRC). However, it...
Perceptions of work stress, burnout, and burnout management strategies among oncologists.
e21003 Background: Often characterized as exhaustion of physical or emotional strength due to prolonged stress or frustration, physician burnout has becom...
Laparoscopic versus open liver resection for colorectal liver metastasis: An individual participant data meta-analysis of randomized controlled trials.
3560 Background: Laparoscopic surgery for colorectal liver metastases (CRLM) is associated with lower physical impact, shorter length of stay and less pos...
Oncology risk score as predictor of unplanned readmissions.
e23166 Background: Almost 75% of our center’s cancer patients with advanced disease are hospitalized at least once in the year following diagnosis. To avo...